title: BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.
abstract: Among the most exciting developments in the field of heart failure in recent times has been the rediscovery of the natriuretic peptide system and its pleuripotent effects on cardiac structure and function. This is particularly true of its natriuretic and hemodynamic effects. There has been an explosion of the knowledge base seeking to understand the wide range of homeostatic, regulatory, and counter-regulatory functions in which the natriuretic peptide system participates. Additional interest has been stimulated by advances in technology such as point-of-care and core laboratory BNP assays and the use of the recombinant B-type natriuretic peptide nesiritide as a treatment option. Despite this recent interest, the available literature lacks a comprehensive expert review of the current science and roles of natriuretic peptides for diagnostic, prognostic, screening, treatment monitoring, and therapeutic purposes. More importantly, a summary updating and guiding the clinician on most of these advances was lacking. An expert Consensus Panel with basic, methodological, and clinical expertise was convened to summarize current knowledge in these areas and the findings and consensus statements are contained herein.
authors.affiliation: Department of Medicine and Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL 60453-2600, USA. marc.silver@advocatehealth.com
authors.forename: Marc A
authors.initials: MA
authors.lastname: Silver
authors.forename: Alan
authors.initials: A
authors.lastname: Maisel
authors.forename: Clyde W
authors.initials: CW
authors.lastname: Yancy
authors.forename: Peter A
authors.initials: PA
authors.lastname: McCullough
authors.forename: John C
authors.initials: JC
authors.lastname: Burnett
authors.forename: Gary S
authors.initials: GS
authors.lastname: Francis
authors.forename: Mandeep R
authors.initials: MR
authors.lastname: Mehra
authors.forename: William Franklin
authors.initials: WF
authors.lastname: Peacock
authors.forename: Gregg
authors.initials: G
authors.lastname: Fonarow
authors.forename: W Brian
authors.initials: WB
authors.lastname: Gibler
authors.forename: David A
authors.initials: DA
authors.lastname: Morrow
authors.forename: Judd
authors.initials: J
authors.lastname: Hollander
mesh_terms: D009320:Atrial Natriuretic Factor / Q000502:physiology; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D032921:Consensus; D006801:Humans; D008171:Lung Diseases / Q000378:metabolism; D045283:Natriuretic Agents / Q000627:therapeutic use; D020097:Natriuretic Peptide, Brain / Q000502:physiology*; D009765:Obesity / Q000378:metabolism; D017410:Practice Guidelines as Topic; D011379:Prognosis; D051437:Renal Insufficiency / Q000378:metabolism; D014218:Triage
chemical_list: D045283:Natriuretic Agents; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor